1. 89 A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML). Issue 1 (April 2015) Authors: Navada, S.C.; Garcia-Manero, G.; Hearn, K.; Odchimar-Reissig, R.; Demakos, E.; Alvarado, Y.; Daver, N.; DiNardo, C.; Konopleva, M.; Borthakur, G.; Azarnia, N.; Silverman, L.R. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS). (April 2017) Authors: Navada, S.; Garcia-Manero, G.; Hearn, K.; Odchimar-Reissig, R.; Demakos, E.; Fenaux, P.; Petrone, M.; Zbyszewski, P.; Fruchtman, S.; Silverman, L. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P746: COMBINATION OF RAS/MAPK MODULATOR AND AZACITIDINE AFFECTS HISTONE MARKS AND IMPACTS THE INNATE IMMUNE SIGNALING PATHWAY IN THE MDS-L CELL LINE. (23rd June 2022) Authors: Rai, R.; Patel, F.; Feld, J.; Melana, S.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.; Reddy, E. P.; Horowitz, A.; Silverman, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 641 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: THE COMBINATION OF A RAS SIGNALING MODULATOR WITH AZACITIDINE IMPROVES HEMATOPOIESIS IN VIVO AND HAS IN VITRO EFFECTS ON METABOLIC/DIFFERENTIATION PATHWAYS AND INNATE IMMUNE SIGNALING. (September 2021) Authors: Rai, R.; Patel, F.; Melana, S.; Feld, J.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.; Reddy, E.P.; Silverman, L. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ABERRANT IMMUNE LANDSCAPE IN BONE MARROW OF HIGH-RISK MYELODYSPLASTIC SYNDROME PATIENTS. (May 2023) Authors: Rai, R.; Patel, F.; Feld, J.; Melana, S.; Demakos, E.; Horowitz, A.; Silverman, L. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗